1. 患者招募受阻,辉瑞终止一CD47药物试验日前,行业媒体Endpoints News报道,辉瑞宣布终止CD47药物maplirpacept联合化疗药来那度胺用于复发或难治性弥漫大B细胞淋巴瘤(DLBCL)患者的Ⅱ期临床试验。辉瑞发言人表示,试验终止的原因是“招募困难,并非出于安全性或疗效方面的担忧”。发言人还表示,公司仍在推进该药物用于治疗包括多发性骨髓瘤在内的多种血液恶性肿瘤的研究。此次试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.